New Mexico, USA 21/6/2018 – Indica Labs, Inc announced today that the HALO® platform was used in two recent research papers that describe novel digital
12 July 2018 | This webinar is a “must see” for anyone interested in PD-1/PD-L1 targeted immunotherapy and quantitative methods for biomarker assessment in immuno-oncology. In this webinar, Dr. Viktor Koelzer from the Institute of Cancer and Genomic Science at the University of Birmingham and the Wellcome Trust Centre for Human Genetics at the University of Oxford will discuss these critical areas of improvement within the context of two recent studies published by the presenter and his colleagues.
Computational pathology: A new platform to empower personalized immunotherapy Read More »
Viktor H. Koelzer, et al, Nature Medicine, 2018. Immune checkpoint inhibitors have become a successful treatment in metastatic melanoma. The high response rates in a subset of patients suggest that a sensitive companion diagnostic test is required. The predictive value of programmed death ligand 1 (PD‐L1) staining in melanoma has been questioned due to inconsistent correlation with clinical outcome. Whether this is due to predictive irrelevance of PD‐L1 expression or inaccurate assessment techniques remains unclear. The aim of this study was to develop a standardised digital protocol for the assessment of PD‐L1 staining in melanoma and to compare the output data and reproducibility to conventional assessment by expert pathologists.
Digital image analysis improves precision of PD‐L1 scoring in cutaneous melanoma Read More »
Evidence from mouse chronic viral infection models suggests that CD8+T cell subsets characterized by distinct expression levels of the receptor PD-1 diverge in their state
21 June 2018 | In this 60-minute webinar, Indica Labs is pleased to welcome two guest speakers who will discuss how they are using the RNAscope assay with HALO® quantification software in their institutions. Dr. Gordon Jiang from Beth Israel Deaconess Medical Center | Harvard Medical School will present his original research including the use of chromogenic RNAscope and HALO to analyze PNPLA3 transcirption in Non-Alchoholic Liver Disease (NAFLD). Dr. Julia Jones from Cancer Research UK | Cambridge Institute will explain the RNAscope technology in more depth and give examples of how the histopathology/ISH core facility utilizes HALO for quantification of single/dual chromogenic and multiplexed fluorescent RNAscope probes to answer research questions posed by investigators within the institute. Full abstracts for individual presentations can be found below.
RNAscope ISH Quantification using the HALO® Image Analysis Platform Read More »
The neurotrophic tyrosine kinase receptor TrkA (NTRK1) and its ligand nerve growth factor (NGF) are emerging promoters of tumor progression. In lung cancer, drugs targeting
Anorexigenic pro-opiomelanocortin (Pomc)/alpha-melanocyte stimulating hormone (αMSH) neurons of the hypothalamic melanocortin system function as key regulators of energy homeostasis, also controlling somatic growth across different
Pancreatic ductal adenocarcinoma (PDA) is a lethal malignancy resistant to most therapies, including immune checkpoint blockade. To elucidate mechanisms of immunotherapy resistance, we assessed immune
Indica Labs invites you to attend our 2018 Digital Pathology & AI Lunch & Learn Monday June 25, 2018Radisson Martinique on BroadwayNew York City, NY1:30
Indica Labs Digital Pathology & AI USA Lunch & Learn Read More »
Indica Labs invites you to attend our 2018 Tokyo User Group Meeting Tuesday May 8, 2018Keio Plaza Hotel TokyoShinjuku-Ku, Tokyo, Japan Indica Labs invites you to
INDICA LABS TOKYO QUANTITATIVE PATHOLOGY & AI USER GROUP MEETING Read More »
